ehealth radio network
Douglas Dieterich, M.D., discusses role of FibroScan in the diagnoses of chronic liver disease

Douglas Dieterich, M.D., discusses role of FibroScan in the diagnoses of chronic liver disease

July 22, 2021

 

Douglas_Dieterich6b6hd.png

 

Douglas Dieterich, M.D., director of the Institute for Liver Medicine, Mount Sinai Health System, and professor of medicine for the Division of Liver Disease, Icahn School of Medicine at Mount Sinai joins eHealth Radio and the Health News and Technology Channels to discuss noninvasive liver screening to halt the progression of liver disease.


Listen to interview with host Eric Michaels and guest Dr. Douglas Dieterich discuss the following:

  1. Please share with us the importance of ongoing assessment of liver stiffness and fat as part of a liver health assessment?
  2. What role does FibroScan play in the diagnoses of chronic liver diseases and cirrhosis?
  3. What is the risk of hepatocellular carcinoma (HCC) in people with long-term liver diseases, and if the liver is scarred by infection with hepatitis B or hepatitis C?
  4. Tell us more about the use of FibroScan in hospital settings to improve outcomes and reduce costs in the assessment of liver disease.
  5. Where do you see this going in terms of management and improving outcomes?

Dr. Douglas Dieterich is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY.

He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases.

Douglas T. Dieterich graduated from Yale University in New Haven, CT and received his Doctorate of Medicine from New York University of Medicine in NY. He completed his internship and residency in Internal Medicine at the Bellevue Hospital Center in New York, NY where he was also a fellow in the Division of Gastroenterology. He became Clinical Assistant Professor of medicine and then a Clinical Professor of Medicine, both at the New York University. He remains as an Adjunct Clinical Professor of Medicine at New York University School of Medicine.

Dr. Dieterich is an investigator for many ongoing clinical trials evaluating the safety and efficacy of new antiviral treatments for chronic hepatitis B & C.

Dr. Dieterich is a member of many professional societies and is a fellow of both the American College of Physicians and the American College of Gastroenterology. He has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH), including the Steering Committee of the Opportunistic Infections Core Committee and the Cytomegalovirus (CMV) Committee. He was Chair and Co-Chair, respectively, of the Enteric Parasites Committee and the Protozoan Committee. He also served on the NIH Study Sections for CMV and cryptosporidiosis.

Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS associated infections of the gastrointestinal tract and liver.

logo_echosens_gradient6xp78.png

Website: https://echosens.com

Social Media Links:
Facebook: facebook.com/fibroscan.echosens 
Linkedin: linkedin.com/company/echosens 
Youtube: youtube.com/user/EchosensTV
Twitter: twitter.com/Echosens

Plus Therapeutics: Gliblastoma, Rhenium NanoLiposome, and Harnessing the Power of Radiation Therapy

Plus Therapeutics: Gliblastoma, Rhenium NanoLiposome, and Harnessing the Power of Radiation Therapy

July 15, 2021

 

Dr_Mark_Hedrick8ef5z.png

 

Dr. Marc Hedrick, President and CEO at Plus Therapeutics which is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system joins eHealth Radio and the Cancer Information and Health News Channels.


Listen to interview with host Eric Michaels and guest Dr. Marc Hedrick discuss the following:

  1. What is Plus Therapeutics, and what is its mission?
  2. Tell us about your background and what brought you to Plus Therapeutics?
  3. What is Rhenium NanoLiposome (RNL™) and how is it delivered to cancerous brain tumors?
  4. How could RNL help advance current treatment options for GBM and why is this important for patients?
  5. Do you think most people understand radiation and its potential benefits as a cancer therapy?
  6. What do you think is the most common misconception that people hold about radiation as a cancer treatment?
  7. What’s next Plus Therapeutics? Is Plus developing other investigational candidates as part of its broader pipeline?

Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.

 

PLUS-06-e1559589501420.jpg

 

Website: plustherapeutics.com

Social Media Links:
Facebook: facebook.com/plustherapeutics 
Instagram: instagram.com/plustherapeutics 
Twitter: twitter.com/plustxinc
Linkedin: linkedin.com/company/plustherapeutics

Talking With One of America’s Top Facial Cosmetic Surgeons!

Talking With One of America’s Top Facial Cosmetic Surgeons!

July 10, 2021

 

Dr_Daria_Hamrahb3j82.png

 

Dr. Daria Hamrah, a top Double Board Certified Oral and Maxillofacial / Facial Cosmetic Surgeon in the US joins eHealth Radio and the Beauty and Health News & Plastic Surgery Information Channels.


Listen to interview with host Eric Michaels and guest Dr. Daria Hamrah discuss the following:

  1. What procedures have people been getting most during the pandemic?
  2. What new types of technology have you been using these days that is really changing the game?
  3. With your charity foundation, tell us about it and why is providing services to kids in Colombia so important to you?
  4. What tips can you give people when selecting a facial cosmetic surgeon?
  5. What else do you have planned for 2021?

Dr. Daria Hamrah is a top double Board Certified oral and maxillofacial / facial cosmetic surgeon in America. When he isn't performing surgeries, Dr. Hamrah is also the co-founder of a non-profit called “The Alegria Foundation”, which helps children with cleft lip and palate and facial deformities; Dr. Hamrah travels to Colombia yearly and donates his time performing cleft lip procedures for the children there.


Website: https://novasurgicare.com

Social Media Links:
Facebook: facebook.com/NOVASURGICARE
Instagram: instagram.com/drhamrah
Twitter: twitter.com/realdrhamrah
YouTube: youtube.com/user/drhamrah

Echosens CEO Discusses How Company Helps Fight Liver Disease Epidemic

Echosens CEO Discusses How Company Helps Fight Liver Disease Epidemic

July 5, 2021

 

Jon_Gingrich_2021ah5vj.png

 

Jon Gingrich, the CEO of Echosens North America, a high-technology company offering the FibroScan family of products joins eHealth Radio and the Health News & Technology Channels.


Listen to interview with host Eric Michaels and guest Jon Gingrich discuss the following:

  1. Please share with us the ongoing need for liver health assessment – and why the detection of fatty liver disease remains such a pressing challenge for Americans.

  2. Please tell our audiences about the 2021 Echosens corporate initiatives and its focus on halting the progression of non-alcoholic fatty liver disease (NAFLD), fibrosis and cirrhosis. Describe new goals and objectives for building on the progress that Echosens has made in 2020.
  3. Explain how Echosens plans to further expand the use of FibroScan technology in healthcare systems across America.

  4. Can you describe specific programs and services to help educate specialists on the role of FibroScan?

  5. How is Echosens helping payers and employers to understand the value of FibroScan?

  6. Tell us about Echosens’ FAST score implementation and what successes you are seeing as a result of its use.

  7. Explain how the COVID-19 pandemic has highlighted opportunities for Echosens to solve new problems, and support innovations that advance preventive care, address critical health care needs and improve outcomes for more Americans.
  8. What is Echosens’ focus to continue bringing this awareness of NAFLD diagnosis and treatment in a post-pandemic world?

About Jon Gingrich, CEO, Echosens North America

With more than 20 years of global medical device and health care sales, marketing and general management experience at AxoGen, Inc., Hologic, Inc., Boston Scientific Corporation and Unilever, N.V, Gingrich now leads the development and execution of the Echosens U.S. strategy for expanding the utilization of FibroScan® technology in the assessment of chronic liver disease. As a member of the broader global executive leadership team, he works to implement the Company’s transformation plan and shape the future of Echosens.

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.

logo_echosens_gradient6xp78.png

Website: https://echosens.com

Social Media Links:
Facebook: facebook.com/fibroscan.echosens 
Linkedin: linkedin.com/company/echosens 
Youtube: youtube.com/user/EchosensTV

Community is Key:  The final push for herd immunity

Community is Key: The final push for herd immunity

July 1, 2021

 

Alexis_Hunter98ce2.jpeg

 

Alexis Hunter, Community Liaison for Wilmington Health, a physician-owned primary care and multi-specialty medical practice serving Wilmington and the Southeastern North Carolina area joins eHealth Radio and the COVID-19, Health Care and Health News Channels.


Listen to interview with host Eric Michaels & guest Alexis Hunter discuss the following:

  1. What current trends are we seeing with vaccinations across the U.S.?
  2. What has changed over the past six months that the vaccine has been available?
  3. How are rural/lower-income areas effected?
  4. Has one demographic been more hesitant than another?
  5. How are you continuing to get the word out in your community?

Alexis joined Wilmington Health, one of the largest independent, multi-specialty practices in North Carolina, in April 2020. Recruited as the first dedicated outreach employee for the organization, she focuses on building relationships with organizations and individuals in southeastern North Carolina. Alexis dedicates herself to Wilmington Health’s vision of aspiring to be the most trusted partner in healthcare, transforming the delivery system, and continually developing collaborative and innovative solutions that demonstrate quality, reduce the cost of care, and improve the patient experience.

Before joining Wilmington Health, she worked in administration for a private mental health practice. She works closely with area employers to ensure employees have access to expert healthcare. She also collaborates with outside providers, so that patients in the community have access to the providers that can best suit their healthcare needs.

 

wilmington_health9ocxx.jpeg

 

Website: wilmingtonhealth.com

Social Media Links:
Facebook: facebook.com/wilmingtonhealth 
Instagram: @wilmhealth
LinkedIn: linkedin.com/company/wilmington-health-associates

Podbean App

Play this podcast on Podbean App